Isobel Pearson, DPhil

Director, Health Economics, Health Technology Assessment

DPhil, Molecular Biology and Biochemistry

University of Oxford, UK

BSc (Hons), Biochemistry with Intercalated Year

University of Warwick, UK

Isobel Pearson, DPhil, is a Director of Health Economics, Health Technology Assessment, at RTI-HS. After gaining a DPhil at the University of Oxford, Dr. Pearson worked at Complete Market Access (formerly the Evidence Research Unit), a division of the Complete Medical Group. Dr. Pearson focused on projects where she was able to develop a detailed and in-depth understanding of the technology in question and its place in therapy.

Dr. Pearson's experience both as Technical Lead and Director of Health Economics includes the development of clinical and economic systematic literature reviews, targeted literature reviews, health technology assessment submissions, cost-effectiveness and budget-impact analyses, core value dossiers, objection handling materials, key opinion leader interviews, and publications. Dr. Pearson’s therapy area experience includes rare diseases; psoriasis; endocrinology; rheumatoid arthritis; hepatic, hematologic, diabetic, and endocrine diseases; oncology; and cardiovascular disease.